Related Experiment Video
Updated: Aug 5, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Integrated multi-omics characterization of SMAD4 mutant colorectal cancer
Danyi Zhao1, Yanjun Qu1, Na Gao2
1Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Abstract:
Colorectal cancer is one of the most common cancers around the world, which is a severe threat to people's health. SMAD4 belongs to the dwarfin/SMAD family, which plays a crucial role in TGF-β and BMP signal pathways. As the molecular characterization of colon cancer patients following SMAD4 mutations remains unclear, we integrated multi-omics data of SMAD4 mutant patients to reveal the profile of molecular characterization of SMAD4 mutation. A missense mutation is the most common mutant type of SMAD4. Patients with SMAD4 mutation had worse survival. Tumor tissues from patients carrying the SMAD4 mutation showed a reduction in various immune cells, such as CD4 + memory T cells and memory B cells. Many differential genes were identified compared to the SMAD4 mutation-free group and could be significantly enriched for tumor- and immune-related signaling pathways. In addition, the mutant group had different drug sensitivities than the non-mutant group.
Insights
SMAD4 mutations in colorectal cancer patients are linked to poorer survival and altered immune cell profiles. This research clarifies the molecular landscape of SMAD4-mutant colon cancer, impacting treatment strategies.
Area of Science:
- Oncology
- Genetics
- Immunology
Background:
- Colorectal cancer (CRC) is a global health concern.
- SMAD4 gene mutations are implicated in various cancers, affecting TGF-β and BMP signaling pathways.
- The precise molecular characteristics of CRC with SMAD4 mutations are not fully understood.
Purpose of the Study:
- To elucidate the molecular characterization of colorectal cancer patients with SMAD4 mutations.
- To integrate multi-omics data for a comprehensive profile of SMAD4-mutant CRC.
- To identify potential therapeutic targets and biomarkers.
Main Methods:
- Integration of multi-omics data from SMAD4 mutant and wild-type colorectal cancer patients.
- Comparative analysis of molecular profiles, including gene expression and immune cell infiltration.
- Assessment of survival outcomes and drug sensitivities.
Main Results:
- Missense mutations are the most frequent type of SMAD4 alteration.
- SMAD4 mutations correlate with significantly worse patient survival.
- Tumor tissues from SMAD4-mutant patients exhibit reduced infiltration of CD4+ memory T cells and memory B cells.
- Differential gene expression analysis revealed pathways enriched in tumor and immune functions.
- Distinct drug sensitivities were observed between SMAD4-mutant and non-mutant groups.
Conclusions:
- SMAD4 mutations define a distinct molecular subtype of colorectal cancer with impaired anti-tumor immunity and poorer prognosis.
- The identified molecular alterations and pathway enrichments offer potential targets for novel therapeutic interventions.
- Understanding SMAD4 mutation status can inform personalized treatment strategies and predict drug responses in CRC.
More Related Videos
10:33Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
